Zobrazeno 1 - 10
of 328
pro vyhledávání: '"David R, Snydman"'
Publikováno v:
Microbiology Spectrum, Vol 12, Iss 8 (2024)
ABSTRACT Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is a serious clinical challenge with high mortality rates. Antibiotic combination therapy is currently used in cases of persistent infection; however, the limited development of n
Externí odkaz:
https://doaj.org/article/73a86c822d9d4f0b8c8d26f09bc0cc9c
Autor:
Whitney A. Perry, MD, MS, Jennifer K. Chow, MD, MS, Jason Nelson, MPH, David M. Kent, MD, MS, David R. Snydman, MD
Publikováno v:
Transplantation Direct, Vol 9, Iss 12, p e1542 (2023)
Background. Invasive infection remains a dangerous complication of heart transplantation (HT). No objectively defined set of clinical risk factors has been established to reliably predict infection in HT. The aim of this study was to develop a clinic
Externí odkaz:
https://doaj.org/article/6927f4c891d049bf888f3482a97773bc
Autor:
Kirthana Beaulac, Claire L. Fellman, Annie S. Wayne, Laura A. McDermott, David R. Snydman, Shira Doron
Publikováno v:
Antimicrobial Stewardship & Healthcare Epidemiology, Vol 3 (2023)
Transmission of bacteria between animals and humans in domestic households is increasingly recognized. We evaluated the presence of antimicrobial-resistant fecal bacteria in 8 dog-owner–dog pairs before and after the dog received amoxicillin-clavul
Externí odkaz:
https://doaj.org/article/ab96ac58dbf4442fa4684d9f7f07e269
Publikováno v:
Antimicrobial Stewardship & Healthcare Epidemiology, Vol 2 (2022)
Abstract Objective: To evaluate the impact of the addition of an indication specification requirement to isolated urine-culture ordering on testing utilization. Design: Retrospective study utilizing interrupted time series analysis with negative b
Externí odkaz:
https://doaj.org/article/42ff22a18b92477fa2743f1baffe09e1
Autor:
David R. Snydman, Laura McDermott
Publikováno v:
Microbiology Spectrum, Vol 9, Iss 3 (2021)
ABSTRACT Aztreonam-avibactam is under clinical development for multidrug-resistant Gram-negative infections. We evaluated in vitro activity against 341 recent clinical isolates. The addition of avibactam to aztreonam had no effect on the anaerobic ac
Externí odkaz:
https://doaj.org/article/a994deb91625400d9b5c552f9e542be8
Autor:
Mayanka Tickoo, Robin Ruthazer, Amit Bardia, Shira Doron, Gabriela M. Andujar-Vazquez, Bradley J. Gardiner, David R. Snydman, Sebastian G. Kurz
Publikováno v:
BMC Pulmonary Medicine, Vol 19, Iss 1, Pp 1-7 (2019)
Abstract Background Despite well-defined criteria for use of antibiotics in patients presenting with mild to moderate Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD), their overuse is widespread. We hypothesized that following im
Externí odkaz:
https://doaj.org/article/ffbbd8fd6ccc480bbbe2e15678709551
Autor:
David R. Snydman, Linden Hu
Publikováno v:
Medicine. 49:747-750
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff81a5725a85d2167a5affbee0ccc7b1
https://doi.org/10.1016/j.mpmed.2021.09.004
https://doi.org/10.1016/j.mpmed.2021.09.004
Autor:
Laura A McDermott, Cheleste M Thorpe, Ellie Goldstein, Audrey Schuetz, Stuart Johnson, Dale N Gerding, Karen C Carroll, Kevin W Garey, Chris Lancaster, Seth Walk, Esther Duperchy, David R Snydman, Linda Gluck, Dimitrios Bourdas
Publikováno v:
Open Forum Infectious Diseases. 9
Background We have previously reported on a US based national surveillance study from 6 geographically dispersed medical centers for the susceptibility and epidemiology of C. difficile isolates. This current survey was conducted with isolates collect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a11d57c090b6f94c9dd1c8e01645ba4
https://doi.org/10.1093/ofid/ofac492.1299
https://doi.org/10.1093/ofid/ofac492.1299
Publikováno v:
Open Forum Infectious Diseases. 9
Background Antibiotic exposure is the most important risk factor for Clostridioides difficile associated diarrhea (CDAD). Little information has been reported on the relationship between prior antibiotic exposure, antibiotic resistance of C. difficil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1a9198ad8ea58fa7ef6d4745c816b64
https://doi.org/10.1093/ofid/ofac492.568
https://doi.org/10.1093/ofid/ofac492.568
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0199810 (2018)
Ridinilazole, a novel targeted antibacterial being developed for the treatment of C. difficile infection (CDI) and prevention of recurrence, was shown in a recent Phase 2 study to be superior to vancomycin with regard to the primary efficacy measure,
Externí odkaz:
https://doaj.org/article/62f7690d5aaa4b0095f88aad8342d6f5